Kyowa Kirin Co., Ltd.

Appendix to the Consolidated Financial Summary (IFRS)
Fiscal 2022 Interim

(January 1, 2022 - June 30, 2022)
The average exchange rates for each period were as follows:

<table>
<thead>
<tr>
<th></th>
<th>FY 2021 results</th>
<th>FY 2022 results</th>
<th>FY 2022 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
<td>Jan - Sep</td>
</tr>
<tr>
<td>USD</td>
<td>105</td>
<td>107</td>
<td>108</td>
</tr>
<tr>
<td>GBP</td>
<td>143</td>
<td>147</td>
<td>149</td>
</tr>
<tr>
<td>CNY</td>
<td>16.1</td>
<td>16.4</td>
<td>16.6</td>
</tr>
</tbody>
</table>

Contact
Kyowa Kirin Co., Ltd.
Corporate Communications Department
Tel +81 3 5205 7206
### 1. Trends in consolidated profit

#### <Accumulative>

The "★" symbol indicates financial KPIs (numerical guidance) that were set as targets in the FY2021-2025 Medium Term Business Plan.

<table>
<thead>
<tr>
<th>Financial KPIs</th>
<th>FY2021-2025 Medium Term Business Plan Financial KPIs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Core EPS (¥/share)*1</td>
<td>-</td>
</tr>
<tr>
<td>Dividend payout ratio (%)*2</td>
<td>43.2</td>
</tr>
<tr>
<td>ROE (%)</td>
<td>7.3</td>
</tr>
<tr>
<td>EPS (Kshare)</td>
<td>24.05</td>
</tr>
<tr>
<td>Core EPS (Kshare)*1</td>
<td>24.00</td>
</tr>
<tr>
<td>Annual dividend (Kshare)</td>
<td>46.00</td>
</tr>
<tr>
<td>Core operating profit ratio</td>
<td>19.1%</td>
</tr>
<tr>
<td>Profit to revenue ratio</td>
<td>15.9%</td>
</tr>
<tr>
<td>Revenue</td>
<td>81.1</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>83.9</td>
</tr>
<tr>
<td>Gross profit</td>
<td>87.9</td>
</tr>
</tbody>
</table>
| Gross profit to revenue ratio | 74.9%

#### <Quarterly>

<table>
<thead>
<tr>
<th>Financial KPIs</th>
<th>FY2022 results</th>
<th>FY2022 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Core operating profit ratio</td>
<td>19.1%</td>
<td>15.8%</td>
</tr>
<tr>
<td>Profit to revenue ratio</td>
<td>15.9%</td>
<td>25% or higher</td>
</tr>
<tr>
<td>EPS (Kshare)</td>
<td>46.67</td>
<td></td>
</tr>
<tr>
<td>Core EPS (Kshare)*1</td>
<td>47.75</td>
<td></td>
</tr>
<tr>
<td>Annual dividend (Kshare)</td>
<td>48.00</td>
<td></td>
</tr>
<tr>
<td>Core operating profit ratio</td>
<td>19.8%</td>
<td>25% or higher</td>
</tr>
<tr>
<td>Profit to revenue ratio</td>
<td>15.2%</td>
<td>55%</td>
</tr>
<tr>
<td>Revenue</td>
<td>88.9</td>
<td></td>
</tr>
<tr>
<td>Cost of sales</td>
<td>106.57</td>
<td></td>
</tr>
<tr>
<td>Gross profit</td>
<td>118.64</td>
<td></td>
</tr>
<tr>
<td>Gross profit to revenue ratio</td>
<td>14.8%</td>
<td></td>
</tr>
<tr>
<td>Core operating profit ratio</td>
<td>19.0%</td>
<td>-</td>
</tr>
<tr>
<td>Profit to revenue ratio</td>
<td>14.7%</td>
<td>-</td>
</tr>
<tr>
<td>EPS (Kshare)</td>
<td>61.25</td>
<td></td>
</tr>
<tr>
<td>Core EPS (Kshare)*1</td>
<td>68.62</td>
<td></td>
</tr>
<tr>
<td>Annual dividend (Kshare)</td>
<td>66.14</td>
<td></td>
</tr>
<tr>
<td>Core operating profit ratio</td>
<td>21.4%</td>
<td>-</td>
</tr>
<tr>
<td>Profit to revenue ratio</td>
<td>14.9%</td>
<td>-</td>
</tr>
<tr>
<td>Revenue</td>
<td>97.43</td>
<td></td>
</tr>
<tr>
<td>Cost of sales</td>
<td>108.57</td>
<td></td>
</tr>
<tr>
<td>Gross profit</td>
<td>109.28</td>
<td></td>
</tr>
<tr>
<td>Gross profit to revenue ratio</td>
<td>21.8%</td>
<td></td>
</tr>
<tr>
<td>Core operating profit ratio</td>
<td>19.5%</td>
<td>-</td>
</tr>
<tr>
<td>Profit to revenue ratio</td>
<td>19.5%</td>
<td>-</td>
</tr>
<tr>
<td>EPS (Kshare)</td>
<td>91.43</td>
<td></td>
</tr>
<tr>
<td>Core EPS (Kshare)*1</td>
<td>97.32</td>
<td></td>
</tr>
<tr>
<td>Annual dividend (Kshare)</td>
<td>100.99</td>
<td></td>
</tr>
<tr>
<td>Core operating profit ratio</td>
<td>19.7%</td>
<td>-</td>
</tr>
<tr>
<td>Profit to revenue ratio</td>
<td>19.8%</td>
<td>-</td>
</tr>
</tbody>
</table>

### Notes

*1 Core EPS is calculated as an indicator showing recurring profitability by dividing core profit (determined by subtracting "other income," "other expenses" and the related "income tax expense" from "profit") by the average number of shares during the period.

*2 Dividend payout ratio is shown based on core EPS.
### 2. Revenue by regional control function

<table>
<thead>
<tr>
<th>Region</th>
<th>FY 2021 results</th>
<th>FY 2022 results</th>
<th>FY 2022 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
<td>Jan - Sep</td>
</tr>
<tr>
<td>Japan</td>
<td>39.2</td>
<td>76.7</td>
<td>114.9</td>
</tr>
<tr>
<td>North America</td>
<td>15.9</td>
<td>34.6</td>
<td>54.2</td>
</tr>
<tr>
<td>EMEA</td>
<td>12.0</td>
<td>25.9</td>
<td>39.8</td>
</tr>
<tr>
<td>Asia/Oceania</td>
<td>6.9</td>
<td>14.3</td>
<td>22.1</td>
</tr>
<tr>
<td>Others</td>
<td>7.1</td>
<td>13.6</td>
<td>23.0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>81.1</strong></td>
<td><strong>165.0</strong></td>
<td><strong>254.0</strong></td>
</tr>
</tbody>
</table>

*Revenue by regional control function is classified based on consolidated revenue from products of regional control functions in the One Kyowa Kirin structure (a global management structure with axes combining four regions – Japan, North America, EMEA, and Asia/Oceania – and the functions needed by a global specialty pharmaceutical company).

**EMEA** consists of Europe, the Middle East, Africa, etc.

**Others** consists of revenue from technology out-licensing, original equipment manufacturing, etc.

### 3. Revenue by location of customer

<table>
<thead>
<tr>
<th>Location</th>
<th>FY 2021 results</th>
<th>FY 2022 results</th>
<th>FY 2022 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
<td>Jan - Sep</td>
</tr>
<tr>
<td>Japan</td>
<td>40.9</td>
<td>79.9</td>
<td>119.1</td>
</tr>
<tr>
<td>International</td>
<td>40.3</td>
<td>85.1</td>
<td>134.9</td>
</tr>
<tr>
<td>Americas</td>
<td>20.6</td>
<td>43.4</td>
<td>69.9</td>
</tr>
<tr>
<td>Of which, the U.S.</td>
<td>20.0</td>
<td>41.7</td>
<td>67.9</td>
</tr>
<tr>
<td>Europe</td>
<td>11.3</td>
<td>24.4</td>
<td>38.2</td>
</tr>
<tr>
<td>Asia</td>
<td>8.2</td>
<td>17.1</td>
<td>26.7</td>
</tr>
<tr>
<td>Others</td>
<td>0.0</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>81.1</strong></td>
<td><strong>165.0</strong></td>
<td><strong>254.0</strong></td>
</tr>
</tbody>
</table>

*Revenue by location of customer is classified by region or country based on location of customer.*

### 4. Capital expenditures (property, plant and equipment) and intangible assets investment

<table>
<thead>
<tr>
<th>Component</th>
<th>FY 2021 results</th>
<th>FY 2022 results</th>
<th>FY 2022 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
<td>Jan - Sep</td>
</tr>
<tr>
<td>Capital expenditures (property, plant and equipment)</td>
<td>2.0</td>
<td>2.8</td>
<td>4.7</td>
</tr>
<tr>
<td>Intangible assets investment</td>
<td>1.6</td>
<td>2.9</td>
<td>11.1</td>
</tr>
<tr>
<td>Total</td>
<td>3.7</td>
<td>5.7</td>
<td>15.8</td>
</tr>
</tbody>
</table>

*Acquisitions of right-of-use assets are not included.*

### 5. Depreciation and amortization

<table>
<thead>
<tr>
<th>Component</th>
<th>FY 2021 results</th>
<th>FY 2022 results</th>
<th>FY 2022 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
<td>Jan - Sep</td>
</tr>
<tr>
<td>Depreciation (property, plant and equipment)</td>
<td>2.8</td>
<td>5.5</td>
<td>8.3</td>
</tr>
<tr>
<td>Amortization (intangible assets)</td>
<td>1.9</td>
<td>3.7</td>
<td>5.6</td>
</tr>
<tr>
<td>Total</td>
<td>4.6</td>
<td>9.2</td>
<td>13.9</td>
</tr>
</tbody>
</table>

### II. Consolidated Statement of Cash Flows

<table>
<thead>
<tr>
<th>Component</th>
<th>FY 2021 results</th>
<th>FY 2022 results</th>
<th>Change amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash flows from operating activities</td>
<td>(14.4)</td>
<td>(23.0)</td>
<td>81.2</td>
</tr>
<tr>
<td>Cash flows from investing activities</td>
<td>(4.6)</td>
<td>(1.9)</td>
<td>(10.8)</td>
</tr>
<tr>
<td>Cash flows from financing activities</td>
<td>(13.5)</td>
<td>(14.3)</td>
<td>(27.6)</td>
</tr>
<tr>
<td>Effect of exchange rate changes on cash and cash equivalents</td>
<td>0.4</td>
<td>(0.1)</td>
<td>0.6</td>
</tr>
<tr>
<td>Net increase (decrease) in cash and cash equivalents</td>
<td>(3.3)</td>
<td>5.7</td>
<td>43.4</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of period</td>
<td>287.0</td>
<td>287.0</td>
<td>287.0</td>
</tr>
<tr>
<td>Cash and cash equivalents at end of period</td>
<td>283.8</td>
<td>292.8</td>
<td>330.4</td>
</tr>
</tbody>
</table>
### III. Revenue from Main Products

**<Accumulative>**

<table>
<thead>
<tr>
<th>Product name</th>
<th>FY 2021 results</th>
<th>FY 2022 results</th>
<th>FY 2022 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
<td>Jan - Sep</td>
</tr>
<tr>
<td><strong>Japan</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nesp</td>
<td>1.0</td>
<td>1.9</td>
<td>2.9</td>
</tr>
<tr>
<td>Darbepoetin Alfa Injection Syringe [KKF]</td>
<td>5.5</td>
<td>11.0</td>
<td>16.7</td>
</tr>
<tr>
<td>Duvroq</td>
<td>0.2</td>
<td>0.5</td>
<td>1.4</td>
</tr>
<tr>
<td>Regpara</td>
<td>0.7</td>
<td>1.5</td>
<td>2.1</td>
</tr>
<tr>
<td>Orkedia</td>
<td>2.1</td>
<td>4.6</td>
<td>7.1</td>
</tr>
<tr>
<td>Rocaltrol</td>
<td>0.7</td>
<td>1.5</td>
<td>2.3</td>
</tr>
<tr>
<td>Onglyza</td>
<td>1.5</td>
<td>3.0</td>
<td>4.6</td>
</tr>
<tr>
<td>Coniel</td>
<td>0.6</td>
<td>1.3</td>
<td>2.0</td>
</tr>
<tr>
<td>Fentos</td>
<td>6.6</td>
<td>13.8</td>
<td>21.2</td>
</tr>
<tr>
<td>Technology out-licensing</td>
<td>0.8</td>
<td>1.8</td>
<td>2.8</td>
</tr>
<tr>
<td><strong>International</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nesp</td>
<td>5.0</td>
<td>9.1</td>
<td>13.9</td>
</tr>
<tr>
<td>Nesp</td>
<td>1.2</td>
<td>2.3</td>
<td>3.5</td>
</tr>
<tr>
<td>Technology out-licensing</td>
<td>0.6</td>
<td>1.3</td>
<td>1.5</td>
</tr>
</tbody>
</table>

* Revenue from products is classified as Japan or International (other than Japan) based on consolidated revenue from regional control functions and technology out-licensing is classified as Japan or International (other than Japan) based on the location of the customer.
* Revenue from main products does not include revenue from the Early Access Program (EAP).
* Revenue listed as “Technology out-licensing” specifies revenue from the upfront payment, milestone revenue, and running royalties revenue that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group’s pipeline compounds or the use of technology, etc.
* Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company’s own estimates).

* Of which, Benralizumab royalty
### III. Revenue from Main Products

**<Quarterly>**

<table>
<thead>
<tr>
<th>Product name</th>
<th>FY 2021 results</th>
<th>FY 2022 results</th>
<th>Change amount</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Apr - Jun</td>
<td>Jul - Sep</td>
</tr>
<tr>
<td>Darbepoetin Alfa Injection Syringe [KKF]</td>
<td>5.5</td>
<td>5.5</td>
<td>5.6</td>
</tr>
<tr>
<td>Duvoq</td>
<td>0.2</td>
<td>0.4</td>
<td>0.8</td>
</tr>
<tr>
<td>Regpara</td>
<td>0.7</td>
<td>0.8</td>
<td>0.7</td>
</tr>
<tr>
<td>Orkedia</td>
<td>2.1</td>
<td>2.5</td>
<td>2.5</td>
</tr>
<tr>
<td>Rocaltrol</td>
<td>0.7</td>
<td>0.8</td>
<td>0.8</td>
</tr>
<tr>
<td>Onglyza</td>
<td>1.5</td>
<td>1.6</td>
<td>1.5</td>
</tr>
<tr>
<td>Coniel</td>
<td>0.6</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td>G-Lasta</td>
<td>6.6</td>
<td>7.2</td>
<td>7.4</td>
</tr>
<tr>
<td>Fentos</td>
<td>0.8</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Poteligeo</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Rituximab BS [KHK]</td>
<td>2.6</td>
<td>2.7</td>
<td>2.8</td>
</tr>
<tr>
<td>Romipride</td>
<td>1.5</td>
<td>1.3</td>
<td>2.1</td>
</tr>
<tr>
<td>Allelock</td>
<td>2.9</td>
<td>1.9</td>
<td>1.4</td>
</tr>
<tr>
<td>Patanol</td>
<td>6.5</td>
<td>1.2</td>
<td>1.5</td>
</tr>
<tr>
<td>Dovobet</td>
<td>1.5</td>
<td>2.0</td>
<td>1.7</td>
</tr>
<tr>
<td>Lumicef</td>
<td>0.6</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td>Nouriast</td>
<td>1.9</td>
<td>2.3</td>
<td>2.2</td>
</tr>
<tr>
<td>HARUROPI</td>
<td>0.6</td>
<td>0.8</td>
<td>0.8</td>
</tr>
<tr>
<td>Depakene</td>
<td>0.8</td>
<td>0.9</td>
<td>1.0</td>
</tr>
<tr>
<td>Crysvita</td>
<td>1.5</td>
<td>1.9</td>
<td>1.8</td>
</tr>
<tr>
<td>Total</td>
<td>0.6</td>
<td>0.7</td>
<td>0.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Japan</th>
<th>Jan - Mar</th>
<th>Apr - Jun</th>
<th>Jul - Sep</th>
<th>Oct - Dec</th>
<th>Jan - Mar</th>
<th>Apr - Jun</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nesp</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
<td>1.1</td>
<td>0.8</td>
<td>0.8</td>
<td>(0.1)</td>
</tr>
<tr>
<td>Pecfent</td>
<td>1.3</td>
<td>1.4</td>
<td>1.5</td>
<td>1.6</td>
<td>1.7</td>
<td>1.8</td>
<td>(0.1)</td>
</tr>
<tr>
<td>Coniel</td>
<td>0.6</td>
<td>0.7</td>
<td>0.7</td>
<td>0.7</td>
<td>0.6</td>
<td>0.5</td>
<td>(0.1)</td>
</tr>
<tr>
<td>Regparra</td>
<td>0.6</td>
<td>0.7</td>
<td>0.8</td>
<td>0.9</td>
<td>0.7</td>
<td>0.8</td>
<td>0.2</td>
</tr>
<tr>
<td>Abstral</td>
<td>1.8</td>
<td>2.2</td>
<td>2.2</td>
<td>2.3</td>
<td>1.4</td>
<td>2.2</td>
<td>(0.0)</td>
</tr>
<tr>
<td>Fentos</td>
<td>0.6</td>
<td>0.7</td>
<td>0.8</td>
<td>0.9</td>
<td>0.7</td>
<td>0.8</td>
<td>0.2</td>
</tr>
<tr>
<td>Gran</td>
<td>1.3</td>
<td>1.7</td>
<td>1.9</td>
<td>1.4</td>
<td>2.1</td>
<td>1.8</td>
<td>0.0</td>
</tr>
<tr>
<td>Technology out-licensing</td>
<td>4.9</td>
<td>4.1</td>
<td>7.3</td>
<td>8.0</td>
<td>7.7</td>
<td>7.6</td>
<td>3.5</td>
</tr>
<tr>
<td>Total</td>
<td>3.8</td>
<td>3.4</td>
<td>4.6</td>
<td>5.1</td>
<td>4.7</td>
<td>4.6</td>
<td>1.2</td>
</tr>
</tbody>
</table>

* Revenue from products is classified as Japan or International (other than Japan) based on consolidated revenue from regional control functions and technology out-licensing is classified as Japan or International (other than Japan) based on the location of the customer.
* Revenue from main products does not include revenue from the Early Access Program (EAP).
* Revenue listed as “Technology out-licensing” specifies revenue from the upfront payment, milestone revenue, and running royalties revenue that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group’s pipeline compounds or the use of technology, etc.
* Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company’s own estimates).
### III. Revenue from Main Products

**Revenue of three global strategic products**

#### <Accumulative>

<table>
<thead>
<tr>
<th>Product name</th>
<th>FY 2021 results</th>
<th>FY 2022 results</th>
<th>FY 2022 forecasts</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Jan - Jun</td>
<td>Jan - Sep</td>
</tr>
<tr>
<td>Crysvita</td>
<td>17.8</td>
<td>38.8</td>
<td>60.2</td>
</tr>
<tr>
<td>Japan</td>
<td>1.5</td>
<td>3.3</td>
<td>5.1</td>
</tr>
<tr>
<td>North America</td>
<td>11.7</td>
<td>25.7</td>
<td>40.3</td>
</tr>
<tr>
<td>EMEA</td>
<td>4.5</td>
<td>9.7</td>
<td>14.8</td>
</tr>
<tr>
<td>Asia/Oceania</td>
<td>-</td>
<td>-</td>
<td>0.0</td>
</tr>
<tr>
<td>Poteligeo</td>
<td>3.6</td>
<td>7.9</td>
<td>12.4</td>
</tr>
<tr>
<td>Japan</td>
<td>0.5</td>
<td>0.9</td>
<td>1.5</td>
</tr>
<tr>
<td>North America</td>
<td>2.6</td>
<td>5.8</td>
<td>9.2</td>
</tr>
<tr>
<td>EMEA</td>
<td>0.6</td>
<td>1.1</td>
<td>1.8</td>
</tr>
<tr>
<td>Nouriast/Nourianz</td>
<td>2.9</td>
<td>6.1</td>
<td>9.4</td>
</tr>
<tr>
<td>Japan</td>
<td>1.9</td>
<td>4.2</td>
<td>6.4</td>
</tr>
<tr>
<td>North America</td>
<td>1.0</td>
<td>1.9</td>
<td>3.1</td>
</tr>
<tr>
<td>Total of three global strategic products</td>
<td>24.2</td>
<td>52.8</td>
<td>82.0</td>
</tr>
</tbody>
</table>

#### <Quarterly>

<table>
<thead>
<tr>
<th>Product name</th>
<th>FY 2021 results</th>
<th>FY 2022 results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jan - Mar</td>
<td>Apr - Jun</td>
</tr>
<tr>
<td>Crysvita</td>
<td>17.8</td>
<td>21.0</td>
</tr>
<tr>
<td>Japan</td>
<td>1.5</td>
<td>1.9</td>
</tr>
<tr>
<td>North America</td>
<td>11.7</td>
<td>14.0</td>
</tr>
<tr>
<td>EMEA</td>
<td>4.5</td>
<td>5.2</td>
</tr>
<tr>
<td>Asia/Oceania</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Poteligeo</td>
<td>3.6</td>
<td>4.3</td>
</tr>
<tr>
<td>Japan</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>North America</td>
<td>2.6</td>
<td>3.2</td>
</tr>
<tr>
<td>EMEA</td>
<td>0.6</td>
<td>0.6</td>
</tr>
<tr>
<td>Nouriast/Nourianz</td>
<td>2.9</td>
<td>3.3</td>
</tr>
<tr>
<td>Japan</td>
<td>1.9</td>
<td>2.3</td>
</tr>
<tr>
<td>North America</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Total of three global strategic products</td>
<td>24.2</td>
<td>28.6</td>
</tr>
</tbody>
</table>

* Revenue is classified based on consolidated revenue from regional control functions.
* Revenue from main products does not include revenue from the Early Access Program (EAP).
### IV. R&D Pipeline

<table>
<thead>
<tr>
<th>Code Name</th>
<th>Generic Name Formulation</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Area</th>
<th>Stage</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>KHK1580</td>
<td>Evocalcet Oral</td>
<td>Calcimimetic</td>
<td>Secondary Hyperparathyroidism</td>
<td>CN Asia</td>
<td>Ph I Filled</td>
<td>[Mitsubishi Tanabe Pharma] product name in Japan: Orkedia</td>
</tr>
<tr>
<td>E-RTA 402</td>
<td>Bardoxolone Methyl Oral</td>
<td>Antioxidant Inflammation Modulator</td>
<td>Alport Syndrome</td>
<td>JP</td>
<td>Ph III Approving</td>
<td>[Reata]</td>
</tr>
<tr>
<td>KW-3357</td>
<td>Antithrombin Gamma injection</td>
<td>Recombinant Human Antithrombin</td>
<td>Preecclampsia</td>
<td>JP</td>
<td>Filed</td>
<td>[In-House] product name in Japan: Acoalan</td>
</tr>
<tr>
<td>KWK1781</td>
<td>Tenapanor Hydrochloride Oral</td>
<td>NHE3 Inhibitor</td>
<td>Hyperphosphatemia in Patients on Dialysis</td>
<td>JP</td>
<td>Filed</td>
<td>[Ardelyx]</td>
</tr>
</tbody>
</table>

#### Oncology

<table>
<thead>
<tr>
<th>Code Name</th>
<th>Generic Name Formulation</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Area</th>
<th>Stage</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>KKW-0761</td>
<td>Mogamulizumab Injection</td>
<td>Anti-CCR4 Humanized Antibody</td>
<td>Mycosis Fungoides and Sizary Syndrome</td>
<td>CA AE IL CN KR KW</td>
<td>Ph II Filled</td>
<td>[In-House] POTEILIGENT® product name in Japan, U.S. and Europe: Poteligeo</td>
</tr>
<tr>
<td>KME-401</td>
<td>Zandelisib Oral</td>
<td>P3K8 Inhibitor</td>
<td>Indolent B-cell Non-Hodgkin's Lymphoma</td>
<td>NA Europe Asia Oceania</td>
<td>Ph III Approved</td>
<td>[MEI Pharma] Combination with rituximab: Second line +</td>
</tr>
<tr>
<td>KKH4827</td>
<td>Brodalumab Injection</td>
<td>Anti-IL-17 Receptor A Fully Human Antibody</td>
<td>Ankylosing Spondylitis</td>
<td>TW</td>
<td>Ph II Approved</td>
<td>[Amgen K-A] product name in Japan: Lumicef</td>
</tr>
<tr>
<td>KKH4803/AMG 451</td>
<td>Rocatinlimab Injection</td>
<td>Anti-OX40 Fully Human Antibody</td>
<td>Atopic Dermatitis</td>
<td>NA Europe</td>
<td>Ph II Approved</td>
<td>[In-House] POTEILIGENT® Human Antibody-Producing Technology Collaboration agreement with Amgen for the development of KKH4803/AMG 451 in all the countries except for Japan.</td>
</tr>
</tbody>
</table>

### Immunology/Allergy

<table>
<thead>
<tr>
<th>Code Name</th>
<th>Generic Name Formulation</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Area</th>
<th>Stage</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>KHK4827</td>
<td>Brodalumab Injection</td>
<td>Anti-IL-17 Receptor A Fully Human Antibody</td>
<td>Ankylosing Spondylitis</td>
<td>TW</td>
<td>Ph II Approved</td>
<td>[Amgen K-A] product name in Japan: Lumicef</td>
</tr>
<tr>
<td>KHK4803/AMG 451</td>
<td>Rocatinlimab Injection</td>
<td>Anti-OX40 Fully Human Antibody</td>
<td>Atopic Dermatitis</td>
<td>NA Europe</td>
<td>Ph II Approved</td>
<td>[In-House] POTEILIGENT® Human Antibody-Producing Technology Collaboration agreement with Amgen for the development of KKH4803/AMG 451 in all the countries except for Japan.</td>
</tr>
</tbody>
</table>

※ Since the development of KHK2455 for solid tumor and urothelial carcinoma was discontinued, the relevant information was deleted from this table.

- Updated since Mar. 31, 2022
- Updated since Dec. 31, 2021

- antibody protein small molecule

- New Molecular Entity
## Central Nervous System

<table>
<thead>
<tr>
<th>Code Name</th>
<th>Generic Name</th>
<th>Formulation</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Area</th>
<th>Stage</th>
<th>[In-House or Licensed]</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>◎ KW-6356 Oral</td>
<td>Adenosine A2A Receptor Antagonist/Inverse Agonist</td>
<td>Parkinson's Disease</td>
<td>JP</td>
<td>[In-House]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>◎ KHK0640</td>
<td>Anti-Amyloid Beta Peptide Antibody</td>
<td>Alzheimer's Disease</td>
<td>JP / Europe</td>
<td>[Immunas Pharma]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Other

<table>
<thead>
<tr>
<th>Code Name</th>
<th>Generic Name</th>
<th>Formulation</th>
<th>Mechanism of Action</th>
<th>Indication</th>
<th>Area</th>
<th>Stage</th>
<th>[In-House or Licensed]</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>KRN23 Burosumab Injection</td>
<td>Anti-FGF23 Fully Human Antibody</td>
<td>X-linked Hypophosphatemia (XLH)</td>
<td>TH / MY / Europe</td>
<td>[In-House] Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU product name in Japan, U.S. and Europe: Crysvita</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMG531 Romiplostim Injection</td>
<td>Thrombopoietin Receptor Agonist</td>
<td>Treatment of Aplastic Anemia (AA) Which Is Refractory to Immunosuppressive Therapy or AA not Amenable to Immunosuppressive Therapy</td>
<td>CN / SG / MY / TH</td>
<td>[Amgen K-A] product name in Japan: Romiplate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KW-3357</td>
<td>Recombinant Human Antithrombin</td>
<td>Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency</td>
<td>Europe</td>
<td>[In-House] product name in Japan: Acoalan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KHK4951 Ophthalmic</td>
<td>Wet Age-Related Macular Degeneration</td>
<td>JP</td>
<td>[In-House]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

※ We decided to discontinue the development of KW-6356 in the central nervous system field in July.